---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-029629"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-04-08T23:59:59+00:00"
generated_at: "2026-05-23T18:57:38.807117+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q1 prelim revenue $39.0M, raises H1 2025 net sales guidance to $62-$70M

## Summary
- Preliminary unaudited Q1 2025 net revenue of $39.0M; expects adjusted EBITDA above $22.5M.
- Raises H1 2025 net sales guidance for existing purchasing customers to $62M-$70M from prior range.
- Cash and short-term investments at March 31, 2025: approx. $77.5M.
- Phase 3 TPN study of DefenCath enrollment expected to begin late April; peak sales potential $150M-$200M.
- Forecasts patient utilization growth in H2 2025; unit shipments expected to exceed H1 2025.

## SEC filing metadata
- accession: 0001213900-25-029629
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-04-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/0001213900-25-029629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025029629/ea023738701-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-029629
- JSON: https://secwatch.observer/filing/0001213900-25-029629.json
- Plain text: https://secwatch.observer/filing/0001213900-25-029629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.